SAN FRANCISCO, April 22 - Cepheid's new CEO, John Bishop, started his job last Monday.

He is currently commuting between his home in Chicago and Cepheid's Sunnyvale, Calif., headquarters. While he is in sticker shock from shopping for a house in Silicon Valley, Bishop seems very much at home in what he sees as his role to build Cepheid from a tool concern into a "patient disease-management" company.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.